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Purpose: To report a case of juvenile xanthogranuloma involving the iris and skin that clincally was
diagnosed with an obvious cutaneous lesion.
Observations: A four month-old girl with hyphema and increased intraocular pressure of the left eye
persisting for 2 weeks. A suspicious yellow-brown mass with nodular surface and traversed by irregular
vascularization was noted on the inferior iris surface. Ultrasound biomicroscopy (UBM; 35 MHz) of the
mass revealed multiple nodular irregular hyperreﬂective lesions in the peripheral iris. Using a biopsy of
an obvious cutaneous abdominal skin lesion a diagnosis was made based on histopathological analyses.
The biopsy showed dense dermal inﬁltrate consisting of foamy histiocytes. Additional stains revealed
CD68 positivity and CD1a and S100 negativity. This mass revealed histopathologic features identical to
juvenile xanthogranuloma and was concurrent with the iris lesion. Next-generation sequencing using Ion
AmpliSeqTM Cancer Hotspot Panel revealed a missense mutation of FGFR3 (p.F386L).
Conclusion and importance: The diagnosis of a xanthogranuloma of the iris with hyphema can be made
easier in patients with obvious cutaneous lesions as described in our case. The signiﬁcance of FGFR3
mutation in association with JXG is unknown and should be further investigated.
© 2017 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Juvenile xanthogranuloma (JXG) is a rare benign hystiocytic pro-
liferation most common in infants and young children. Typically it
manifests primarily as a self-limited dermatologic disorder and con-
sists of solitary ormultifocal yellow-pink cutaneousnodules.1 JXGcan
rarely be associated with extracutaneous sites including mostly the
eye. Ocular JXG typically manifests as a circumscript iris nodule, oc-
casionally with hyphema and elevated intraocular pressure.2 We
describe a caseof nodular iris JXGwithassociated skin lesionofwhich
an additional molecular-pathological examination was performed.
2. Case report
2.1. Clinical history
A four month-old girl was referred to our eye clinic for cloudi-
ness and redness of the left eye which had persisted for 2 weeks.n open access article under the CCThe medical history including pregnancy and birth was unre-
markable. The parents denied any history of trauma or signs for
allergy. The child presented with an increased intraocular pressure
(IOP) of the left eye of 40 mmHg (right eye 16 mmHg), mild edema
of the cornea and primary hyphema up to the pupillary edge which
later developed into a “pseudohypopyon”. Slight anisocoria was
observed. To reduce the IOP, treatment was started with local
acetazolamide and b-blocker (twice a day) and topical steroid
(three times a day). Ten days later, left eye, IOP had decreased to
16 mm Hg and hyphema regressed. A suspicious yellow-brown
mass with irregular vascularisation was noted on the inferior iris
surface. In addition, heterochromia with green left iris and blue
right iris was obvious.
During further physical examination we found one yellowish-
brown papule on the abdomen of the child (Fig. 2A). Under gen-
eral anaesthesia, ultrasound biomicroscopy of the yellow brown
mass on the iris surface (UBM; 35 MHz) revealed multiple nodular
irregular hyperreﬂective lesions in the peripheral iris between 2
and 7 o'clock, growing into the anterior chamber angle and towards
the corneal endothelium. The pigmented epithelium of the iris was
intact, the ciliary body was not involved (Fig. 1A and B).BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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late phase. Retinal examination of the posterior pole of both eyes
and B-scan echography showed no lesion in the vitreous, retina/
choroidea or optic nerve thus a retinoblastoma was ruled out.
Under the same general anaesthesia the papule on the abdomen
was totally excised and submitted for histological examination.
2.2. Dermal pathology
Histology of the cutaneous abdominal skin lesion showed a
dense dermal inﬁltrate consisting of histiocytes, some lymphocytes
and plasma cells without touton giant cells. The overlying
epidermis was focally attenuated. The histiocytes were mostly
mononuclear with a narrow cytoplasmic rim and cytoplasmic
vacuoles, reaching focally up to the epidermis. Immunohis-
tochemically, the histiocytic phenotype was conﬁrmed with a
positive staining for CD68. Langerhans cell histiocytosis was ruled
out with a negative reaction for CD1a and S100. A malignant lym-
phoma could be excluded (Fig. 2).
2.3. Molecular pathology
DNA was extracted from parafﬁn tissue. Next-generation
sequencing from the tumor tissue was performed using an Ion
AmpliSeqTM Cancer Hotspot Panel v2: A BRAF mutation as
described for Langerhans cell histiocytosis3 could be excluded.
Instead, FGFR3 missense mutation (p.F386L) was found, so far
undescribed in Juvenile Xanthogranuloma (Fig. 3).
Treatment was initiated with topical high-dose corticosteroid
(every 2 hours during waking hours and ointment at bedtime) with
a slow taper. During the next month the iris lesion decreased
completely without recurrence of hyphae or iritis and after three
weeks the therapy with corticosteroids was stopped (Fig. 1C and D).
However a secondary esotropia with deep amblyopia of the left eye
was observed. Visual acuity (VA) was measured using Teller AcuityFig. 1. Clinical evaluation of the iris lesion. A. A Yellow-brown mass with irregular vasculari
(dorzolamid/timolol and topical steroid). B. Ultrasound biomicroscopy of the anterior segme
between 2 and 7 o'clock, growing into the anterior chamber angle and to the corneal endoth
lesion decreased completely without recurrence of hyphae or iritis. D. Ultrasound biomicroCards. VA was 4.8 cy/cm at 38 cm (corresponding to VA 20/180) in
the right eye and 0.86 cy/cm at 38 cm (corresponding to VA 20/
1000) in left eye. After correction of the hyperopia with sph þ4.0
glasses for both eyes as well as an occlusion therapy with patching
of the non-amblyopic eye for 2.5 hours/day were started. After 5
months the visual outcome increased in the left eye to 2.4 cy/cm
(corresponding to VA 20/360; lower limit of normal value).2.4. Diagnosis
Diagnosis of juvenile xanthogranuloma (JXG) was made based
on the histology obtained from a cutaneous lesion. Genetically, a
missense mutation of the FGFR3 gene (p.F386L) with unknown
signiﬁcance was found.3. Discussion
JXG is a rare benign histiocytic proliferation most common as
benign cutaneous disorder in infants and young children. It is
regarded as the common form of non-Langerhans cell histiocy-
tosis.4 Extracutaneous JXG can affect the eye and ocular adnexa as
well as central nervous system, lung, liver, spleen and other sites.
Eye involvement is rather rare with a range of 0.3%e10% of children
with cutaneous JXG.1 Ocular JXG preferentially affects the iris and
can potentially lead to blinding complications such as hyphema,
secondary glaucoma and amblyopia.5 In a survey of 449 iris tumors
occured in children (less than 20 years old) 14 (3%) were xan-
thogranulomatous lesions.6 In another study of Chang MW et al.
cutaneous lesions have been found in up to 40% of children with
ocular JXG.1,7
Spontaneous hyphema with or without increase of intraocular
pressure e in our case with an increased IOP - is a common sign of
iris JXG. The differential diagnosis of hyphema in childhood in-
cludes trauma, neoplastic conditions like retinoblastoma,zation at the inferior part of the iris surface; became visible after ten days of treatment
nt revealing multiple nodular hyperreﬂective heterogenous mass in the peripheral iris
elium (section at 5 o'clock). C. After 2 month of high-dose corticosteroid treatment iris
scopy conﬁrming decrease of iris lesion (section at 5 o'clock).
Fig. 2. Histopathological analyses of the skin lesion. A. Abdominal skin lesion used for histopathological evaluation. B. Hematoxylin and eosin staining (20x) showing dense dermal
inﬁltrate consisting of histiocytes, some lymphocytes and plasma cells. Touton giant cells were not detected. A 60magniﬁcation of the respective area is shown in the lower right
corner. C. Positive CD68 staining (20x) for conﬁrmation of the histiocytic phenotype. D. Negative CD1a and S100 staining (20x) ruling out Langerhans cell histiocytosis.
Fig. 3. Molecularpathological analyses of the skin lesion. Next-generation sequencing using Ion AmpliSeqTM Cancer Hotspot Panel v2 revealing FGFR3 (p.F386L) missense mutation.
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blood dyscrasias and should clinically be ruled out.5
UBM as well as anterior segment optical coherence tomography
can help conﬁrm the diagnosis, demonstrating the iris nodular le-
sions with intact iris pigment epithelium like in our case or
demonstrating ﬂat lesions on the iris surface in other pattern of
JXG.8 In atypical presentations and lesions of poor response to
steroid a ﬁne-needle aspiration biopsy is recommended.9 The
diagnosis can be easier made in patients with obvious cutaneous
lesions like in our case.
Pathologically a Langerhans cell histiocytosis has been excluded
with a CD 1a negative staining of the histiocytes. In early stage of
JXG touton giant cells could not be detected like in our case.10 The
pathogenesis of JXG is still unclear. Although well-charcterised by
morphology and immunohistology the genetic proﬁle of JXG is not
yet elucidated.
Genetically a missense mutation of FGFR3 (p.F386L) was found.
The FGFR3 p.F386L mutation has been reported in patients with
cancer11 and aggressive ﬁbromatosis.12 In addition FGFR3 muta-
tions have been identiﬁed in benign acanthotic skin tumors such as
in seborrheic keratoses and epidermal nevi.13,14 However, the bio-
logical signiﬁcance of this mutation in JXG is unknown.
Therapeutically there is no standard of care for the ophthalmic
manifestation of JXG. Nonsurgical approaches are preferred
because of less risk of intraocular bleeding. Corticosteroids are
recommended as principal therapy. Topical application starting
with a regimen every 2 hours a day, then slowly tapering over a
time period of 3e4 month would be preferred.5 Systemic cortico-
steroids are generally avoided and only considered in uncontrolled
lesions of the iris. The control rate with topical corticosteroids alone
is 63% with a mean duration of 8 weeks.5 To avoid the danger of
amblyopia the therapy should be started as fast as possible. In our
case a secondary esotropia with deep amblyopia of the left eye was
observedwhich required an adequate therapy. In two childrenwith
JXG refractory to local administration of corticosteroid the suc-
cessful use of off-label intraocular bevacizumab was reported.
Bevacizumab was administered leading to reduced vascularity and
ﬂattening of the JXG lesion 3 months after treatment. The authors
suggest that intraocular bevacizumab has a lower risk of cataract
formation and secondary glaucoma than topical corticosteroids.15
4. Conclusions
In summary we report a case of JXG based on the histology
obtained from a cutaneous lesion. Genetically a missense mutation
within the FGFR3 genewas found. The biological signiﬁcance of this
mutation in JXG is unknown. Clinically imaging of the iris with
ﬂuorescein angiography, UBM aided in the detection and the dif-
ferential diagnosis of the iris lesion leading to hyphema and sec-
ondary glaucoma. With use of topical corticosteroids the JXG was
successfully treated, however a secondary esotropia with deep
amblyopia of the left eye was observed.
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